| “Pseudocavitation” in thymic carcinoma during treatment with sunitinib M Tiseo, A Rajan, A Thomas, G Giaccone Journal of Thoracic Oncology 8 (4), 511-512, 2013 | 2 | 2013 |
| 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in … MRG Campelo, E Felip, B Besse, MC Dols, E Quoix, ACM Flandin, ... Annals of Oncology 33, S1020, 2022 | | 2022 |
| 1024P Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 … ME Buyse, F Montestruc, JC Chiem, V Deltuvaite-Thomas, S Salvaggio, ... Annals of Oncology 33, S1022-S1023, 2022 | | 2022 |
| 10th Conference on DNA Topoisomerases in therapy G Giaccone, G Capranico Drug Resistance Updates 2 (6), 347-350, 1999 | 2 | 1999 |
| 1115 POSTER Epidermal Ggrowth Factor Receptor Inhibitor (EGFRI)-associated rash: a suggested novel management paradigm. A consensus position from the EGFRI Dermatologic … G Giaccone, B Melosky, M Reck EJC Supplements 4 (5), 146, 2007 | | 2007 |
| 120 Expression of lung resistance-related protein (LRP) in lung cancer AMC Dingemans, J van Ark-Otte, P Van Der Valk, RJ Scheper, ... European Journal of Cancer 31, S28-S29, 1995 | 5 | 1995 |
| 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 … G Giaccone, E Felip, M Cobo, RG Campelo, F Denis, E Quoix, ... Annals of Oncology 31, S814-S815, 2020 | 12 | 2020 |
| 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced … K Papadopoulos, T Li, N Lakhani, J Powderly, T George, DGK Teoh, ... Immuno-Oncology and Technology 16, 2022 | 1 | 2022 |
| 176 POSTER Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors P Schöffski, V Grünwald, G Giaccone, R Salazar, M Majem, H Dumez, ... Ejc Supplements 12 (6), 56, 2008 | 3 | 2008 |
| 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors A Thomas, E Mena, K Kurdziel, D Venzon, S Khozin, AW Berman, ... Clinical Cancer Research 19 (6), 1487-1493, 2013 | 23 | 2013 |
| 18Fluorodeoxyglucose Positron Emission Tomography, a Standard Diagnostic Tool in Lung Cancer G Giaccone Journal of the National Cancer Institute 99 (23), 1741-1743, 2007 | 6 | 2007 |
| 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer CG Azzoli, S Temin, T Aliff, S Baker Jr, J Brahmer, DH Johnson, JL Laskin, ... Journal of clinical oncology 29 (28), 3825-3831, 2011 | 427 | 2011 |
| 211 Expression of topoisomerase IIalpha;(TOPIIα), lung resistance-related protein (LRP) and multidrug resistance-related protein (MRP) in advanced non-small cell lung cancer … AMC Dingemans, J van Ark-Otte, P van der Valk, GV Scagliotti, G Ferrari, ... Lung Cancer, 55, 1997 | | 1997 |
| 239 Randomized trial of surgery versus radiotherapy in patients with stage IIIA non-small cell lung cancer after a response to induction-chemotherapy. Intergroup study 08941 TAW Splinter, A Kirkpatrick, S Darwish, J van Meerbeeck Lung Cancer, 62-63, 1997 | 18 | 1997 |
| 258 Biology and treatment of thymoma G Giaccone Ejc Supplements 7 (8), 84, 2010 | | 2010 |
| 2ND LINE CHEMOTHERAPY IN OVARIAN-CANCER AFTER FAILURE OF PLATINUM-BASED FRONT TREATMENT M Bruzzone, S Chiara, PF Conte, R Rosso, G Giaccone, F Carnino, ... JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 5 (1), 79-83, 1986 | 4 | 1986 |
| 3 to 5 manuscripts R Alfieri, R Aly, S Arulananda, T Berghmans, P Bironzo, L Bubendorf, ... Journal of Thoracic Oncology 18 (4), 377-378, 0 | | |
| 30 Immunotherapy in advanced NSCLC—from the ‘tsunami’of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the … F de Marinis, F Ciardiello, P Baas, L Crinò, G Giaccone, F Grossi, ... ESMO open 3 (4), e000298, 2018 | 10 | 2018 |
| 312 The prognostic role of mesothelin expression and its association with KRAS mutation in advanced lung adenocarcinoma A Thomas, Y Chen, S Steinberg, J Luo, G Giaccone, I Pastan, M Miettinen, ... European Journal of Cancer, 102, 2014 | | 2014 |
| 33 P-A model to assess cost-effectiveness of prophylaxis of febrile neutropenia J Bussels, G Giaccone, P Postmus, T Sahmoud, T Splinter, K Torfs European Journal of Cancer 32, S7, 1996 | | 1996 |
